抗血管生成疗法的生物标志物：我们如何从候选生物标志物转变为有效的生物标志物？ - Suppr

Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

作者信息

Duda Dan G, Ancukiewicz Marek, Jain Rakesh K

出版信息

J Clin Oncol. 2010 Jan 10;28(2):183-5. doi: 10.1200/JCO.2009.24.8021. Epub 2009 Nov 30.

DOI:10.1200/JCO.2009.24.8021

PMID:19949009

Abstract

摘要

相似文献

Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

J Clin Oncol. 2010 Jan 10;28(2):183-5. doi: 10.1200/JCO.2009.24.8021. Epub 2009 Nov 30.

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.

Med Oncol. 2016 Oct;33(10):105. doi: 10.1007/s12032-016-0824-y. Epub 2016 Aug 27.

Improving efficacy of the combination between antiangiogenic and chemotherapy: Time for mathematical modeling support.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3453. doi: 10.1073/pnas.1506689112. Epub 2015 Jun 16.

Reply to Ciccolini et al.: Using mathematical modeling to predict response to antiangiogenic therapy in cancer patients.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3454. doi: 10.1073/pnas.1507225112. Epub 2015 Jun 16.

Modulation of chemotherapeutic efficacy by vascular disrupting agents: optimizing the sequence and schedule.

J Clin Oncol. 2012 Mar 1;30(7):760-1; author reply 761-3. doi: 10.1200/JCO.2011.39.3934. Epub 2012 Jan 30.

The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis.

Clin Lung Cancer. 2017 May;18(3):255-258. doi: 10.1016/j.cllc.2016.12.001. Epub 2017 Jan 5.

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.

Oncotarget. 2016 Apr 12;7(15):20109-23. doi: 10.18632/oncotarget.7915.

New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.

J Cancer Res Clin Oncol. 2020 Mar;146(3):631-645. doi: 10.1007/s00432-020-03129-6. Epub 2020 Feb 17.

Serum concentrations of vascular endothelial growth factor in advanced non-small cell lung cancer.

Clin Chem. 2003 Mar;49(3):523-5. doi: 10.1373/49.3.523.

In focus: non-small cell lung cancer: E1505.

Clin Adv Hematol Oncol. 2007 Mar;5(3):206-8.

引用本文的文献

Role of aneuploid circulating tumor cells and CD31 circulating tumor endothelial cells in predicting and monitoring anti-angiogenic therapy efficacy in advanced NSCLC.

Mol Oncol. 2021 Nov;15(11):2891-2909. doi: 10.1002/1878-0261.13092. Epub 2021 Sep 12.

Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors.

Mol Cancer Ther. 2018 Jul;17(7):1602-1612. doi: 10.1158/1535-7163.MCT-17-1066. Epub 2018 Apr 25.

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2.

Sci Transl Med. 2018 Mar 14;10(432). doi: 10.1126/scitranslmed.aag0945.

Bevacizumab in the treatment of NSCLC: patient selection and perspectives.

Lung Cancer (Auckl). 2017 Dec 14;8:259-269. doi: 10.2147/LCTT.S110306. eCollection 2017.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.

Obesity and Cancer: An Angiogenic and Inflammatory Link.

Microcirculation. 2016 Apr;23(3):191-206. doi: 10.1111/micc.12270.

Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Am J Transl Res. 2015 Oct 15;7(10):1675-98. eCollection 2015.

Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?

Oncotarget. 2016 Jan 19;7(3):2313-28. doi: 10.18632/oncotarget.6320.

Lower Ras expression as an independent predictor of patient outcomes in lung cancer treated with bevacizumab plus chemotherapy.

Cancer Gene Ther. 2014 Mar;21(3):110-4. doi: 10.1038/cgt.2014.5. Epub 2014 Feb 28.

Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer.

ISRN Cell Biol. 2012;2012. doi: 10.5402/2012/587259.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献